Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors.

Mary Ellen MolloyRichard J AustinBryan D LemonWade H AaronVaishnavi GantiAdrie JonesSusan D JonesKathryn L StrobelPurbasa PatnaikKenneth SextonLaurie TatalickTimothy Z YuPatrick A BaeuerleChe-Leung LawHolger Wesche

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

HPN536 is potent, is well tolerated, and exhibits extended half-life in NHPs. It is currently in phase I clinical testing in patients with MSLN-expressing malignancies (NCT03872206).

Keyphrases

protein protein
stem cells
cell therapy
binding protein
bone marrow
small molecule